FIELD: medicine; medical genetics.
SUBSTANCE: invention can be used for minimally invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) in obese patients. The miR-423-5p and let-7a-5p microRNA expression levels are analyzed by real-time PCR and MIP-1 concentrationsβ enzyme immunoassay in the blood plasma of obese patients. To calculate the NAFLD coefficient, the obtained data are substituted into the calculation formula. If the coefficient of NAFLD is 6.8 or higher, the presence of NAFLD is diagnosed in obese patients, if the coefficient is less than 6.8, the absence of NAFLD is diagnosed.
EFFECT: method enables minimally invasive diagnosis of NAFLD in obese patients by using the formula for calculating the NAFLD coefficient based on the values of miR-423-5p and let-7a-5p expression levels and MIP-1 concentrationβ in blood plasma.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR NON-ALCOHOLIC HEPATIC STEATOSIS BASED ON BLOOD PLASMA microRNA DETECTION | 2023 |
|
RU2831056C1 |
| METHOD FOR DIAGNOSING HEPATIC PATHOLOGIES IN DOGS USING CFA-MIRNAS | 2020 |
|
RU2758950C1 |
| ANALYTICAL SYSTEM FOR DIAGNOSING LUNG CANCER USING FREE AND CIRCULATING MICRO-RNAS ASSOCIATED WITH BLOOD CELLS | 2020 |
|
RU2755651C1 |
| METHODS FOR PATHOLOGICAL CHANGES DETECTION IN ORGAN OR SYSTEM OF ORGANS | 2012 |
|
RU2626540C2 |
| SET OF OLIGODEOXYRIBONUCLEOTIDE PRIMERS FOR DIAGNOSING CARDIOVASCULAR DISEASES AND DETECTING RISK OF THEIR DEVELOPMENT BASED ON BIOMOLECULAR MARKER microRNA hsa-miR-143-5p BY QUANTITATIVE PCR AND USE THEREOF | 2025 |
|
RU2838258C1 |
| DIAGNOSTIC TECHNIQUE FOR NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2024 |
|
RU2827361C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF OVARIAN CANCER, OVARIAN CYSTIC GROWTHS AND UTERINE CANCER | 2024 |
|
RU2836527C1 |
| TEST SYSTEM “miR-M-SCREEN” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH COLORECTAL CANCER BASED ON THE LEVEL OF miR-26a AND miR-143 MICRO-RNA IN BLOOD PLASMA | 2022 |
|
RU2786386C1 |
| METHOD OF EARLY DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2022 |
|
RU2798723C1 |
| RECOMBINANT PLASMID DNA CODING microRNA hsa-miR-143-5p, AND ITS USE AS POSITIVE CONTROL IN REAL-TIME PCR FOR DIAGNOSING CARDIOVASCULAR DISEASES AND DETECTING RISK OF THEIR DEVELOPMENT | 2025 |
|
RU2837872C1 |
